Vaxcyte's CEO Parted With Shares for Taxes. Here's What Long-Term Investors Should Know About the Firm
The stock has surged 95% over the past year, and the CEO retains about 447,000 direct shares plus indirect holdings.
Overview
Grant Pickering, the chief executive officer of Vaxcyte, Inc. (NASDAQ:PCVX), disposed of 6,289 shares of common stock in a non-discretionary transaction, according to an SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average sale price ($61.20); post-transaction value based on the September 2 market close ($61.58).
Details
Vaxcyte, Inc. is a clinical-stage biotechnology enterprise headquartered in San Carlos with 507 employees, focused on developing next-generation protein-based vaccines addressing significant gaps in infectious disease prevention. The company's strategic approach leverages advanced conjugate vaccine technology to create multivalent formulations with enhanced immunogenicity and broader pathogen coverage than existing therapeutic options. With a market capitalization of $9.0 billion and a one-year share price appreciation of 95.12%, Vaxcyte represents investor confidence in its clinical pipeline and the substantial market opportunity within the global vaccine sector.
Source
Originally published at www.fool.com.